Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Redbaron2211on Sep 19, 2021 10:11am
277 Views
Post# 33884323

National Investor

National InvestorCompany Spotlight on Sernova Corporation (TSXV-SVA; OTCQB-SEOVF) KEY UNIVERSITY OF MIAMI COLLABORATION SOLIDIFIED: --- Sernova announced (the news RIGHT HERE) on Thursday that it has entered into a research agreement with the University of Miami to advance the development of its Cell Pouch cell therapy platform combined with the novel conformal coating cellular immune protection technology licensed exclusively to the company by the university. As CEO/President Dr. Philip Toleikis wrote to me afterward, "...The announcement today of the U of Miami collaboration is extremely important because elimination of the required immunosuppression medications used to protect cells from immune system attack by coating the cells with conformal coating (to which Sernova owns the worldwide exclusive license) advances Sernova beyond its peers and could significantly expand the treatable patient population to the less sick diabetic patients..." ____________________________________ TOMORROW'S EXCITING WEBINAR! At 1:00 p.m. tomorrow, Dr. Toleikis will be joined by Dr. Alice Tomei, associate professor at the University of Miami. Quoting from Thursday's news release: "...Dr. Alice Tomei, of the renowned Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine, is an associate professor and international expert in immunoprotection and diabetes immunoengineering. As part of this important collaboration, Dr. Tomei and her team is working closely with Sernovas R&D team. The expert teams have developed a series of key preclinical and polymer characterization studies. In addition, work is being conducted to scale-up the conformal coating technology process. The ultimate goal of this work is to support and accelerate the anticipated clinical evaluation of the Cell Pouch platform without the need for immunosuppression in patients with brittle T1D..." During tomorrow's session, Dr. Tomei will discuss the conformal coating technology approach for local cellular immune protection and Sernova will also provide a management update
<< Previous
Bullboard Posts
Next >>